Proliferative activity in invasive breast carcinoma - A comprehensive comparison of MIB-1 immunocytochemical staining in aspiration biopsies to imageanalytic, flow cytometric and histologic parameters
Ml. Ostrowski et al., Proliferative activity in invasive breast carcinoma - A comprehensive comparison of MIB-1 immunocytochemical staining in aspiration biopsies to imageanalytic, flow cytometric and histologic parameters, ACT CYTOL, 45(6), 2001, pp. 965-972
Citations number
46
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
OBJECTIVE: To use MIB-1 antibody to assess proliferative activity in fine n
eedle aspiration (FNA) samples of invasive breast carcinoma and compare the
se results to multiple other measures of proliferative activity,
STUDY DESIGN: FNA slides from 62 patients with invasive breast carcinoma we
re subjected to staining with MIB-1. Quantitative MIB-1 values were compare
d to image analytic proliferative fractions (IPF) obtained from the same FN
As. MIB-1 values were also compared to flow cytometric S-phase fractions (S
PF) and S + G2/M-phase fractions (FPF) and to histologic assessment of mito
tic count (MC) in resected tumors.
RESULTS: MIB-1 values, IPF, SPF, FPF and MC were suitable for evaluation in
55, 53, 50, 50 and 56 cases, respectively. MIB-1 values showed good correl
ation with IPF in FNAs (correlation coefficient =.57, P <. 00001). MIB-1 va
lues also showed correlation with SPF (correlation coefficient =.447, P =.0
03), FPF (correlation coefficient =.325, P=.023) and MC (correlation coeffi
cient =.402, P =.01) in resected tumors.
CONCLUSION. This study supports the use of MIB-1 values obtained from FNA s
amples for assessment of proliferative activity in invasive breast carcinom
a, based on correlation of these values with multiple other parameters of p
roliferative activity. Assessment of these values can play a role in predic
ting prognosis and in selecting patients with invasive carcinoma of the bre
ast for preoperative or adjuvant chemotherapy.